Lisanti Capital Growth LLC purchased a new stake in Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) during the first quarter, according to the company in its most recent filing with the SEC. The firm purchased 25,365 shares of the company's stock, valued at approximately $1,812,000. Lisanti Capital Growth LLC owned about 0.06% of Soleno Therapeutics as of its most recent SEC filing.
Other hedge funds also recently made changes to their positions in the company. AlphaQuest LLC boosted its holdings in shares of Soleno Therapeutics by 1,154.4% in the 4th quarter. AlphaQuest LLC now owns 715 shares of the company's stock valued at $32,000 after purchasing an additional 658 shares during the last quarter. US Bancorp DE acquired a new position in shares of Soleno Therapeutics during the 4th quarter valued at $34,000. Springhill Fund Asset Management HK Co Ltd acquired a new position in shares of Soleno Therapeutics during the 4th quarter valued at $81,000. Avanza Fonder AB lifted its holdings in shares of Soleno Therapeutics by 14.8% during the 1st quarter. Avanza Fonder AB now owns 1,951 shares of the company's stock valued at $144,000 after acquiring an additional 251 shares in the last quarter. Finally, Summit Investment Advisors Inc. lifted its holdings in shares of Soleno Therapeutics by 24.2% during the 4th quarter. Summit Investment Advisors Inc. now owns 2,677 shares of the company's stock valued at $120,000 after acquiring an additional 522 shares in the last quarter. Institutional investors and hedge funds own 97.42% of the company's stock.
Wall Street Analyst Weigh In
SLNO has been the topic of several recent research reports. Cantor Fitzgerald lifted their target price on shares of Soleno Therapeutics from $67.00 to $123.00 and gave the company an "overweight" rating in a report on Thursday, March 27th. Guggenheim lifted their target price on shares of Soleno Therapeutics from $81.00 to $97.00 and gave the company a "buy" rating in a report on Thursday, May 8th. Piper Sandler lifted their target price on shares of Soleno Therapeutics from $93.00 to $145.00 and gave the company an "overweight" rating in a report on Thursday, April 24th. TD Cowen initiated coverage on shares of Soleno Therapeutics in a report on Monday, June 23rd. They set a "buy" rating and a $110.00 target price on the stock. Finally, UBS Group set a $105.00 target price on shares of Soleno Therapeutics in a report on Thursday, March 27th. Ten analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $107.10.
Check Out Our Latest Stock Report on Soleno Therapeutics
Insider Transactions at Soleno Therapeutics
In other news, insider Patricia C. Hirano sold 3,782 shares of the business's stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $70.11, for a total value of $265,156.02. Following the completion of the sale, the insider now owns 27,036 shares of the company's stock, valued at approximately $1,895,493.96. The trade was a 12.27% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 6.40% of the company's stock.
Soleno Therapeutics Stock Performance
Shares of SLNO stock opened at $83.25 on Friday. Soleno Therapeutics, Inc. has a 12 month low of $39.41 and a 12 month high of $86.67. The company has a debt-to-equity ratio of 0.21, a current ratio of 19.64 and a quick ratio of 19.64. The firm has a market capitalization of $4.19 billion, a P/E ratio of -18.02 and a beta of -2.69. The company's fifty day moving average price is $76.59 and its two-hundred day moving average price is $60.09.
Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.95) EPS for the quarter, topping analysts' consensus estimates of ($1.14) by $0.19. On average, research analysts anticipate that Soleno Therapeutics, Inc. will post -3.72 earnings per share for the current fiscal year.
About Soleno Therapeutics
(
Free Report)
Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.
Further Reading
Want to see what other hedge funds are holding SLNO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Soleno Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Soleno Therapeutics wasn't on the list.
While Soleno Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
